ERBB2 and breast cancer: All of these factors would work together to dilute the non‐specific therapeutic response associated with low HER2 expression, and then lead to non‐differential prognosis between HER2‐low/HR‐positive and HER2‐zero/HR‐positive BC after adjusting for potential confounding factors.